

To: ccmo_bifbi@ccmo.nl]
Cc: 5.1.2.e @lumc.nl 5.1.2.e @lumc.nl]
From: 5.1.2.e @lumc.nl
Sent: Thur 25-4-2019 12:04:44
Subject: NL65325.058.18
Received: Thur 25-4-2019 12:04:55
[A1. Aanbiedingsbrief CCMO.pdf](#)
[B5. Substantial amendment notification form 24Apr2019.pdf](#)

Geachte leden van de CCMO,

Bij deze willen wij u graag mededelen dat de klinische studie getiteld 'Near infrared fluorescence imaging in kidney transplantations using ZW800-1 for perfusion assessment: a pilot study', welke geregistreerd staat onder NL65325.058.18, is opgeschort (zie bijlagen voor de aanbiedingsbrief en B5 formulier).

Met vriendelijke groet,

Mede namens 5.1.2.e ,

5.1.2.e

afdeling 5.1.2.e
afzender 5.1.2.e
telefoon 071-526 5.1.2.e
e-mail 5.1.2.e @lumc.nl

aan CCMO
T.a.v. bevoegde instantie (BI)
Parnassusplein 5
2511 VX Den Haag

datum 24 april 2019
onderwerp NL65325.058.18

Geachte leden van de CCMO,

Bij deze willen wij u graag mededelen dat de klinische studie getiteld 'Near infrared fluorescence imaging in kidney transplantations using ZW800-1 for perfusion assessment: a pilot study', welke geregistreerd staat onder NL65325.058.18, is opgeschort.

Bij twee van de vier patiënten die de studiemedicatie hebben ontvangen zijn serious adverse events (SAE's) opgetreden. Deze SAE's zijn gemeld op Toetsingonline. Hoewel op dit moment niet met zekerheid kan worden vastgesteld of er een relatie is tussen de studiemedicatie en deze SAE's, is dit op klinische gronden reden om vooralsnog geen nieuwe patiënten te includeren. In de komende periode zal nader onderzoek plaatsvinden naar een mogelijke relatie met de studiemedicatie. Deze opschorting geldt in elke geval tot 1 juni 2019. Nader bericht hierover volgt.

Met collegiale hoogachting,

5.1.2.e

5.1.2.e

5.1.2.e

5.1.2.e

Substantial Amendment Notification Form (Cf. Section 3.7.b of the *Detailed guidance on the request to the competent authorities for authorisation of a clinical trial on a medicinal product for human use, the notification of substantial amendments and the declaration of the end of the trial*¹)

NOTIFICATION OF A SUBSTANTIAL AMENDMENT TO A CLINICAL TRIAL ON A MEDICINAL PRODUCT FOR HUMAN USE TO THE COMPETENT AUTHORITIES AND FOR OPINION OF THE ETHICS COMMITTEES IN THE EUROPEAN UNION

For official use:

Date of receiving the request :	Grounds for non acceptance/ negative opinion : <input type="checkbox"/> Date :
Date of start of procedure:	Authorisation/ positive opinion : <input type="checkbox"/> Date :
Competent authority registration number of the trial: Ethics committee registration number of the trial :	Withdrawal of amendment application <input type="checkbox"/> Date :

To be filled in by the applicant:

This form is to be used both for a request to the Competent Authority for authorisation of a **substantial** amendment and to an Ethics Committee for its opinion on a **substantial** amendment. Please indicate the relevant purpose in Section A.

A TYPE OF NOTIFICATION

A.1 Member State in which the substantial amendment is being submitted:	
A.2 Notification for authorisation to the competent authority:	X
A.3 Notification for an opinion to the ethics committee:	<input type="checkbox"/>

B TRIAL IDENTIFICATION (*When the amendment concerns more than one trial, repeat this form as necessary.*)

B.1 Does the substantial amendment concern several trials involving the same IMP?² yes <input type="checkbox"/> no X
B.1.1 If yes repeat this section as necessary.

B.2 Eudract number: 2018-000985-12

Full title of the trial : Near-infrared fluorescence imaging in kidney transplantations using ZW800-1 for perfusion assessment: a pilot study

B.3 Sponsor's protocol code number, version, and date: V3, 10Oct2018

C IDENTIFICATION OF THE SPONSOR RESPONSIBLE FOR THE REQUEST

C.1 Sponsor	
C.1.1 Organisation:	Leiden University Medical Center
C.1.2 Name of person to contact:	5.1.2.e
C.1.3 Address :	Albinsudreef 2, 2333 ZA Leiden
C.1.4 Telephone number :	+31 71 526 5.1.2.e
C.1.5 Fax number :	
C.1.6 e-mail:	5.1.2.e @lumc.nl

C.2 Legal representative³ of the sponsor in the European Union for the purpose of this trial (if different from the sponsor)	
C.2.1 Organisation:	
C.2.2 Name of person to contact:	
C.2.3 Address :	
C.2.4 Telephone number :	
C.2.5 Fax number :	
C.2.6 e-mail:	

¹ OJ, C82, 30.3.2010, p. 1; hereinafter referred to as 'detailed guidance CT-1'.

² Cf. Section 3.7. of the detailed guidance CT-1.

³ As stated in Article 19 of Directive 2001/20/EC.

D APPLICANT IDENTIFICATION (please tick the appropriate box)

D.1 Request for the competent authority	
D.1.1 Sponsor	<input type="checkbox"/>
D.1.2 Legal representative of the sponsor	<input type="checkbox"/>
D.1.3 Person or organisation authorised by the sponsor to make the application.	<input checked="" type="checkbox"/>
D.1.4 Complete below:	
D.1.5 Organisation: Leiden University Medical Center	
D.1.6 Name of person to contact: 5.1.2.e	
D.1.7 Address : Albinsudreef 2, 2333 ZA Leiden	
D.1.8 Telephone number : +31 71 526 5.1.2.e	
D.1.9 Fax number :	
D.1.9.1 e-mail: 5.1.2.e@lumc.nl	

D.2 Request for the Ethics Committee	
D.2.1 Sponsor	<input type="checkbox"/>
D.2.2 Legal representative of the sponsor	<input type="checkbox"/>
D.2.3 Person or organisation authorised by the sponsor to make the application.	<input type="checkbox"/>
D.2.4 Investigator in charge of the application if applicable ⁴ :	
• Co-ordinating investigator (for multicentre trial)	<input type="checkbox"/>
• Principal investigator (for single centre trial):	<input type="checkbox"/>
D.2.5 Complete below	
D.2.6 Organisation:	
D.2.7 Name of person to contact:	
D.2.8 Address :	
D.2.9 Telephone number :	
D.2.10 Fax number :	
D.2.11 e-mail:	

E SUBSTANTIAL AMENDMENT IDENTIFICATION

E.1 Sponsor's substantial amendment code number, version, date for the clinical trial concerned: (V3, 10Oct2018)
--

E.2 Type of substantial amendment	
E.2.1 Amendment to information in the CT application form	yes <input type="checkbox"/> no <input type="checkbox"/>
E.2.2 Amendment to the protocol	yes <input type="checkbox"/> no <input type="checkbox"/>
E.2.3 Amendment to other documents appended to the initial application form	yes <input type="checkbox"/> no <input type="checkbox"/>
E.2.3.1 If yes specify:	
E.2.4 Amendment to other documents or information:	yes <input type="checkbox"/> no <input type="checkbox"/>
E.2.4.1 If yes specify:	
E.2.5 This amendment concerns mainly urgent safety measures already implemented ⁵	yes <input type="checkbox"/> no <input type="checkbox"/>
E.2.6 This amendment is to notify a temporary halt of the trial ⁶	yes <input checked="" type="checkbox"/> no <input type="checkbox"/>
E.2.7 This amendment is to request the restart of the trial ⁷	yes <input type="checkbox"/> no <input type="checkbox"/>

⁴ According to national legislation.

⁵ Cf. Section 3.9. of the detailed guidance CT-1.

⁶ Cf. Section 3.10. of the detailed guidance CT-1.

⁷ Cf. Section 3.10. of the detailed guidance CT-1.

E.3	Reasons for the substantial amendment:	
E.3.1	Changes in safety or integrity of trial subjects	yes <input checked="" type="checkbox"/> no <input type="checkbox"/>
E.3.2	Changes in interpretation of scientific documents/value of the trial	yes <input type="checkbox"/> no <input type="checkbox"/>
E.3.3	Changes in quality of IMP(s)	yes <input type="checkbox"/> no <input type="checkbox"/>
E.3.4	Changes in conduct or management of the trial	yes <input type="checkbox"/> no <input type="checkbox"/>
E.3.5	Change or addition of principal investigator(s), co-ordinating investigator	yes <input type="checkbox"/> no <input type="checkbox"/>
E.3.6	Change/addition of site(s)	yes <input type="checkbox"/> no <input type="checkbox"/>
E.3.7	Other change	yes <input type="checkbox"/> no <input type="checkbox"/>
E.3.7.1	If yes, specify:	
E.3.8	Other case	yes <input type="checkbox"/> no <input type="checkbox"/>
E.3.8.1	If yes, specify	

E.4	Information on temporary halt of trial⁸
E.4.1	Date of temporary halt (2019/04/12)
E.4.2	Recruitment has been stopped yes <input checked="" type="checkbox"/> no <input type="checkbox"/>
E.4.3	Treatment has been stopped yes <input checked="" type="checkbox"/> no <input type="checkbox"/>
E.4.4	Number of patients still receiving treatment at time of the temporary halt in the MS concerned by the amendment (0)
E.4.5	Briefly describe (free text): <ul style="list-style-type: none"> • Justification for a temporary halt of the trial The clinical study 'Near-infrared fluorescence kidney transplantation using ZW800-1 for perfusion assessment: a pilot study' has been suspended. In two of the four patients who have received the study medication a serious adverse events (SAE) occurred. These SAEs have been reported in Toetsingonline. Although it cannot be determined with certainty whether there is a relationship between the study medication and reported SAEs, on clinical grounds inclusion has been halted. Further research will be carried out to determine whether there is a possible relationship with the study medication. • The proposed management of patients receiving treatment at time of the halt (<i>free text</i>). Not applicable, as at the time of the halt all included patients had already received the study medication. <p>The consequences of the temporary halt for the evaluation of the results and for overall risk benefit assessment of the investigational medicinal product (<i>free text</i>). No consequences for the evaluation of the results. Further research will be carried out to determine whether there is a possible relationship with the study medication.</p>

F DESCRIPTION OF EACH SUBSTANTIAL AMENDMENT⁹ (*free text*):

Temporarily halt of the clinical study 'Near-infrared fluorescence kidney transplantation using ZW800-1 for perfusion assessment: a pilot study'.

⁸ Cf. Section 3.10. of the detailed guidance CT-1.

⁹ Cf. Section 3.7.c. of the detailed guidance CT-1. The sponsor may submit this documentation on a separate sheet.

G CHANGE OF CLINICAL TRIAL SITE(S)/INVESTIGATOR(S) IN THE MEMBER STATE CONCERNED BY THIS AMENDMENT

G.1 Type of change
G.1.1 Addition of a new site
G.1.1.1 Principal investigator (provide details below)
G.1.1.1.1 Given name
G.1.1.1.2 Middle name (if applicable)
G.1.1.1.3 Family name
G.1.1.1.4 Qualifications (MD.....)
G.1.1.1.5 Professional address
G.1.2 Removal of an existing site
G.1.2.1 Principal investigator (provide details below)
G.1.2.1.1 Given name
G.1.2.1.2 Middle name (if applicable)
G.1.2.1.3 Family name
G.1.2.1.4 Qualifications (MD.....)
G.1.2.1.5 Professional address
G.1.3 Change of co-ordinating investigator (provide details below of the new coordinating investigator)
G.1.3.1 Given name
G.1.3.2 Middle name
G.1.3.3 Family name
G.1.3.4 Qualification (MD.....)
G.1.3.5 Professional address
G.1.3.6 Indicate the name of the previous co-ordinating investigator:
G.1.4 Change of principal investigator at an existing site (provide details below of the new principal investigator)
G.1.4.1 Given name
G.1.4.2 Middle name
G.1.4.3 Family name
G.1.4.4 Qualifications (MD.....)
G.1.4.5 Professional address
G.1.4.6 Indicate the name of the previous principal investigator:

H CHANGE OF INSTRUCTIONS TO CA FOR FEEDBACK TO SPONSOR

H.1 Change of e-mail contact for feedback on application*	
H.2 Change to request to receive an .xml copy of CTA data	<input type="checkbox"/> yes <input type="checkbox"/> no
H.2.1 Do you want a .xml file copy of the CTA form data saved on EudraCT?	<input type="checkbox"/> yes <input type="checkbox"/> no
H.2.1.1 If yes provide the e-mail address(es) to which it should be sent (up to 5 addresses):	
H.2.2 Do you want to receive this via password protected link(s) ¹⁰ ?	<input type="checkbox"/> yes <input type="checkbox"/> no
If you answer no to question H.2.2 the .xml file will be transmitted by less secure e-mail link(s)	
H.2.3 Do you want to stop messages to an email for which they were previously requested?	<input type="checkbox"/> yes <input type="checkbox"/> no
H.2.3.1 If yes provide the e-mail address(es) to which feedback should no longer be sent:	
(*This will only come into effect from the time at which the request is processed in EudraCT).	

¹⁰

This requires a EudraLink account. (See <https://eudract.ema.europa.eu/> for details)

I LIST OF THE DOCUMENTS APPENDED TO THE NOTIFICATION FORM (cf. Section 3.7 of detailed guidance CT-1)

Please submit only relevant documents and/or when applicable make clear references to the ones already submitted. Make clear references to any changes of separate pages and submit old and new texts. Tick the appropriate box(es).

I.1 Cover letter	X
I.2 Extract from the amended document in accordance with Section 3.7.c. of detailed guidance CT-1 (if not contained in Part F of this form)	<input type="checkbox"/>
I.3 Entire new version of the document ¹¹	<input type="checkbox"/>
I.4 Supporting information	<input type="checkbox"/>
I.5 Revised .xml file and copy of initial application form with amended data highlighted	<input type="checkbox"/>
I.6 Comments on any novel aspect of the amendment if any :	

J SIGNATURE OF THE APPLICANT IN THE MEMBER STATE

J.1	I hereby confirm that/ confirm on behalf of the sponsor that (delete which is not applicable)
	<ul style="list-style-type: none">• The above information given on this request is correct;• The trial will be conducted according to the protocol, national regulation and the principles of good clinical practice; and• It is reasonable for the proposed amendment to be undertaken.

J.2	APPLICANT OF THE REQUEST FOR THE COMPETENT AUTHORITY (as stated in section D.1):X
J.2.1	Signature: 5.1.2.e
J.2.2	Print name:
J.2.3	Date: 24 April 2019

J.3	APPLICANT OF THE REQUEST FOR THE ETHICS COMMITTEE (as stated in section D.2): <input type="checkbox"/>
J.3.1	Signature ¹³ :
J.3.2	Print name:
J.3.3	Date :

¹¹ Cf. Section 3.7.c. of the detailed guidance CT-1.

¹² On an application to the Competent Authority only, the applicant to the Competent Authority needs to sign.

¹³ On an application to the Ethics Committee only, the applicant to the Ethics Committee needs to sign.